Date:

Medical scheme cover can depend on how you use it

As medical schemes communicate their contribution increases and benefit changes for 2027, members will naturally compare the costs and benefits of different options. The Council for Medical Schemes issued its guidance for the 2027 benefit year at the end of July.

But there is something else to consider beyond the costs. Medical scheme benefits can work differently depending on the provider used, the medicine prescribed, whether prior approval was obtained, and the rules attached to the benefit. A member can therefore have cover for a particular healthcare need and still end up paying part of the cost personally.

The CMS has previously pointed to this gap in understanding. In its 2023/24 annual report, the regulator noted complaints where schemes had applied their registered rules correctly, but members did not understand the benefit rules or limits that applied. It also identified confusion around pre-authorisation, treatment protocols, formularies, and scheme tariffs.

PMB cover still comes with rules

Prescribed Minimum Benefits (PMB) give medical scheme members access to a defined minimum level of healthcare, regardless of the benefit option they have selected. That protection does not mean every provider or treatment route will be funded in exactly the same way.

Medical schemes may appoint designated service providers, commonly called DSPs, for the diagnosis and treatment of PMB conditions. If a member voluntarily chooses another provider, a co-payment may apply in line with the scheme’s registered rules.

In some circumstances, using a non-DSP is not treated as a voluntary choice. The regulations recognise situations where appropriate treatment is not reasonably available through the DSP or where the member needs immediate care and cannot reasonably use the designated provider. The funding position is different in those circumstances.

Knowing that a condition qualifies as a PMB is therefore only part of the picture. Members should also know which providers the scheme expects them to use before treatment is needed.

The medicine on the prescription can make a difference

A formulary is the list of medicines a scheme uses when funding treatment for particular conditions. Where a member voluntarily chooses medicine outside that formulary, additional costs may arise.

The CMS says that where the formulary medicine is ineffective or causes adverse effects, a member can appeal to the scheme. If appropriate clinical evidence supports the need for an alternative, the scheme must provide and fund an appropriate substitute under the PMB rules.

For someone using chronic medication, this makes it important to understand both the formulary and the process for motivating an alternative where there is a clinical reason to do so.

Authorisation does not settle everything

Obtaining authorisation for a hospital admission or procedure is important where the scheme requires it. It does not necessarily mean every account linked to the treatment will be paid in full. CMS guidance states that authorisation does not guarantee payment because claims remain subject to the member’s benefits and registered scheme rules.

Before planned treatment, it is worth checking which hospitals and providers the option covers and whether you could still face a co-payment or a shortfall between the provider’s fee and the amount the scheme pays.

Where members can still end up paying

The CMS’s 2024 Industry Report found that medicines made up 35.09% of estimated out-of-pocket spending in 2024 and specialist services 28.47%. The report notes that the calculation does not capture every amount members pay themselves, so it only gives part of the picture.

Even so, they show why members need to understand more than the headline benefit. Having medical scheme cover does not mean every cost will be paid in full. What a member must pay depends on the option’s rules and what the healthcare provider charges.

It also helps clarify terminology. A co-payment required under the scheme rules is not necessarily the same as a shortfall created because a healthcare provider charges more than the amount reimbursed by the scheme. They may have the same effect on the member’s bank account, but they arise for different reasons.

Understand the route to the benefit

Benefit summaries remain useful, but they do not tell the whole story. As members compare options for 2027, they should look beyond whether a benefit appears in the schedule and understand how it must be used. That includes knowing which providers apply, when approval is required, and whether formularies or treatment protocols affect the benefit.

The answers differ between schemes, benefit options, and individual circumstances. Two people can therefore both have medical aid and still have very different experiences when they need treatment.

The annual review period gives members an opportunity to understand those rules before a claim puts them to the test.

Share post:

spot_img

Popular

spot_img

More like this
Related

Nedbank unveils twice-daily, same-day iKhokha settlements at Township Economy Alliance Summit

New payments capability gives qualifying Nedbank-banked iKhokha merchants access...

Metropolitan asks the question insurance should have asked years ago

With more than four million funeral policies lapsing in...

South Africa’s vape tax could be rewarding higher nicotine consumption, says Kurt Yeo

THR Global contributor urges Treasury to examine whether taxing...